分类： health

A walk down a 5-kilometer road in Miraj, a mid-sized regional town in India’s western state of Maharashtra, offers a clear snapshot of a seismic shift reshaping India’s healthcare landscape: more than 50 new multi-specialty hospitals, diagnostic hubs and private clinics line the route, almost all built in just the last five years. This proliferation of private care facilities is far from an isolated trend. It is the visible marker of an unprecedented boom that has swept India’s private healthcare industry over the past decade, transforming access to care while sparking urgent debate over systemic inequality and affordability.

Across the country, private hospital groups are expanding at breakneck speed, adding thousands of new beds every quarter to meet rising demand. Diagnostic chains are rapidly extending their reach into tier-2 and tier-3 towns that were long underserved by formal healthcare, while leading medical institutions are tapping public markets to raise hundreds of millions of dollars for nationwide expansion. In early August 2026, Manipal Health, India’s largest multi-specialty hospital chain, pulled in nearly $1 billion through an initial public offering (IPO), marking the country’s second-biggest public market debut of the year.

Global private equity investors have also flocked to the sector, lured by India’s growing demand for healthcare as incomes rise and chronic disease rates increase. Data from consulting firm Grant Thornton shows that between 2022 and 2024, Indian healthcare and pharmaceutical companies closed nearly 600 merger and acquisition (M&A) and private equity deals worth a combined $30 billion. Forty percent of that total investment went directly to hospital operators, and the BBC’s analysis of additional Grant Thornton data reveals the sector has raised a further $20 billion in just the past two years.

While this wave of investment has dramatically expanded the overall availability of healthcare infrastructure across India, it has also pushed life-saving care out of reach for millions of low- and middle-income citizens, deepening a national affordability crisis that has sparked alarm among policymakers and public health experts. A new government advisory panel report has laid bare the stark inequality at the heart of India’s fast-growing private healthcare economy, warning that unregulated growth is leaving vulnerable households at severe financial risk.

The panel’s analysis found that the cost of treatment at private hospitals is typically 5 to 10 times higher than at comparable public sector facilities. The gap grows even wider for patients battling high-cost chronic and critical illnesses including cancer, heart disease and kidney failure. The report also points out that unbridled expansion of small clinics, nursing homes and diagnostic centers, paired with inconsistent enforcement of national regulatory standards, has created huge disparities in both care quality and pricing across the private sector. This lack of oversight leaves patients exposed to arbitrary pricing and widespread substandard care practices.

Rampant commercialization of private healthcare, the report adds, has driven a surge in patient complaints over excessive billing, unnecessary diagnostic testing, and exorbitant costs for routine procedures such as childbirth. These inflated costs are directly pushing vulnerable households into catastrophic, life-altering debt, forcing many to sell assets or deplete decades of savings to cover medical bills. The crisis of unregulated pricing was highlighted earlier this month when Maharashtra’s food and drug regulator discovered that private hospitals in the state were selling intravenous (IV) fluid sets with a staggering profit margin of 2,800%, a mark-up that regulators noted is almost entirely unmonitored under current rules.

To address these systemic gaps, the government panel has put forward a sweeping set of policy recommendations, including several highly contentious proposals. Among the most debated ideas are a cap on private hospital room rates capped at the average rate of a local three-star hotel, mandatory price regulation for essential treatments, diagnostic services and routine procedures across all private facilities, and enforced standard treatment guidelines to cut down on unnecessary over-treatment. The panel also issued a red flag over foreign ownership exceeding 51% of large domestic hospital chains.

India’s private healthcare industry has pushed back aggressively against many of these proposals, arguing that price caps will stifle future investment and slow the expansion of much-needed care capacity. In an official statement to the BBC, Siddhartha Bhattacharya, Secretary General of NATHEALTH, the leading industry association for India’s private healthcare sector, said policymakers should focus on cutting structural costs that drive up care prices including high taxes, expensive land, costly capital, strict regulatory compliance fees and high skilled labor costs, rather than imposing arbitrary rate caps.
Bhattacharya noted that healthcare delivery is an extremely capital-intensive and investment-heavy sector, with return on capital employed hovering around just 10% — far lower than the 15-25% returns common in many other sectors of the Indian economy. He also rejected the comparison of hospital room pricing to three-star hotel rates, arguing that the analogy overlooks the costly mandatory compliance standards that hospitals must meet, including rigorous infection control protocols and patient safety requirements that add significantly to operating costs.

Leaders of India’s largest hospital chains, including Max Healthcare and Fortis, have echoed these concerns, warning that arbitrary price caps will drive away domestic and foreign investors alike, who will exit the market if they cannot guarantee fair returns on the large upfront capital investments required to build and operate hospitals.

Despite industry pushback, public health experts argue that price regulation is a necessary intervention, noting that India’s private healthcare market currently operates entirely as an unregulated seller’s market that gives providers near-total control over pricing. “With large amounts of foreign private equity flowing into the sector, especially for advanced tertiary care, pricing decisions are increasingly being made by stakeholders outside of India, and that is not a sustainable model,” Dr. Srinath Reddy, president of the Public Health Foundation of India, told the BBC.

Vivek ND, a leading New Delhi-based health policy expert, added that government intervention is particularly critical given the super-sized profits many large hospital chains are currently earning from unregulated pricing. “The growing trend of hospitals pushing patients to undergo dozens of unnecessary tests and unneeded procedures needs urgent scrutiny,” he noted. Vivek welcomed some of the panel’s more moderate proposals, such as a restructuring of India’s goods and services tax regime to lower costs for healthcare providers and patients, but called for broad consultations with all stakeholders before any binding policy changes are implemented.

Dr. Reddy echoed that view, noting that before any blanket price caps are imposed, policymakers need to conduct full nationwide surveys to calculate the actual cost of delivering private care across different regions. “Healthcare costs vary widely from state to state and between large cities and small towns, so a one-size-fits-all national cap simply will not work,” he explained.

As the debate over regulation heats up, public health experts across the board agree that the long-term solution to India’s healthcare affordability crisis lies in drastically expanding public sector healthcare capacity to reduce citizen dependence on expensive private facilities. This is a core recommendation of the government panel’s report itself.

Currently, India’s central government spends just 1.4% of its gross domestic product (GDP) on public healthcare, falling far short of the 2.5% target set out in the National Health Policy nearly a decade ago, and a fraction of the 5% of GDP the World Health Organization recommends as a minimum for strong public health systems. The government panel’s report notes that chronically underinvestment in public secondary and tertiary care has pushed millions of Indians to seek care from private facilities, leading to the catastrophic out-of-pocket health spending that pushes 6 million Indians into poverty every year, according to World Bank data.

“The Indian government has to step up its investment in public healthcare dramatically to reduce the ordinary person’s dependence on private hospitals,” Vivek said. Yet policymakers face a difficult balancing act: estimates show India needs an additional $300 billion in healthcare investment over the next decade to meet growing demand for care, and the vast majority of that capital will have to come from private domestic and foreign investors.

That leaves policymakers with the unenviable task of crafting regulation that protects ordinary patients from exploitative pricing without driving away the investment India needs to expand overall care capacity. The outcome of this debate will shape the health and financial security of hundreds of millions of Indians for decades to come.

Decades have passed since Bangladesh has faced a public health crisis of this scale: a rampant measles outbreak that has already claimed the lives of more than 1,000 children, with daily new suspected cases continuing to climb even after a nationwide emergency vaccination initiative. As of mid-September 2026, official data records more than 194,000 confirmed infections since the outbreak began accelerating in March, pushing the South Asian nation to the unenviable position of recording more measles cases than any other country worldwide this year. Up until March, both the World Health Organization (WHO) and global public health bodies had praised Bangladesh for making substantial progress toward full measles elimination, making the sudden resurgence all the more alarming.

The unfolding crisis traces its roots to a perfect storm of overlapping systemic and public health challenges, according to UNICEF. Years of disruptions to routine childhood immunization caused by the COVID-19 pandemic left a large cohort of children unprotected against the highly contagious virus, which spreads easily through respiratory droplets from coughing, sneezing, and breathing. Bangladesh’s dense population of 178 million people further accelerated transmission, while widespread childhood malnutrition—an ongoing public health challenge in the country—has amplified the risk of severe complications and death for infected children. WHO data confirms the scope of the vaccination gap: 83% of all confirmed measles cases occur in unvaccinated children, with another 10% affecting infants under six months old, a group too young to receive routine measles vaccination and thus inherently vulnerable to the disease.

Disputes over vaccine access and delayed public health action have added another layer of complexity to the crisis. UNICEF has alleged that the former interim government led by Muhammad Yunus delayed placing vaccine orders in 2024 while reviewing proposals from new vendors, despite repeated warnings about the growing risk of an outbreak. “We were worried about possible [vaccine] gaps increasing, and it’s unfolding into what we’re now seeing,” Miguel Mateos Muñoz, a UNICEF spokesperson, told the BBC in June. Senior health officials from Yunus’ administration have denied these claims, asserting that no vaccine shortage ever occurred. Political upheaval in the country over the past two years—including 2024 mass student-led protests that ousted long-time authoritarian prime minister Sheikh Hasina—has further disrupted public health planning and response efforts.

More than 19.8 million children have been vaccinated through the initial emergency campaign, but public health experts agree the first phase of the response fell short of what was needed to curb transmission. Dr Mushtuq Husain, a leading Bangladeshi public health expert, told the BBC that the first campaign failed to reach enough unvaccinated children across all regions and age groups, leaving large pockets of vulnerability. “There are no shortcuts when it comes to a response,” Husain said. “The government made the right decision to jump into action. But the health workers needed to go door-to-door to make people aware of the urgency.” While the WHO has characterized the initial vaccination drive as broadly successful, it acknowledged that a significant share of target children were never reached, and transmission had already spread across every region of the country before large-scale immunization efforts could get underway. “The outbreak spread nationwide before vaccination activities were implemented, creating extensive transmission chains that take time to fully interrupt,” the WHO said in a statement.

Starting September 26, the Bangladeshi government will launch an intensified second phase of its vaccination campaign, aimed at reaching the thousands of unvaccinated children who were missed in the first round. Right now, an average of 1,000 new suspected cases are reported every day, with eight new deaths recorded on a single Tuesday in September, and 300 additional child deaths recorded since the health ministry declared the outbreak under control in June. Hospitals across the country remain overwhelmed by the surge of patients: during a BBC visit to facilities in June, dozens of families were forced to wait and rest on blankets on hospital floors, with one major facility operating at more than twice its intended patient capacity. While the health ministry previously acknowledged the strain on the national health system, it argued that the pressure was unavoidable given Bangladesh’s large population and claimed the crisis had already been contained.

Bangladesh is not an isolated case: measles outbreaks have reemerged across the globe in recent years, even in nations that had previously achieved elimination status. The United Kingdom lost its official measles elimination status earlier this year, and the United States has recorded consistent increases in cases since 2020. In both high-income nations, vaccination coverage for children under five years old falls short of the 95% herd immunity threshold required to stop sustained measles transmission, underscoring the global nature of the growing threat of vaccine-preventable disease resurgence.

In a significant response to a rapidly worsening public health crisis, the Pacific island nation of Fiji has officially declared a national emergency following a sharp surge in HIV infections that has stretched the country’s already fragile health services to breaking point. As national authorities move to scale up testing, treatment, and preventive care across the archipelago, new data reveals the alarming pace at which the epidemic has grown over the past five years.

Today, roughly one out of every 60 adults in Fiji lives with the bloodborne virus, a marked jump from the 2020 figure of one in 167. Compounding the crisis, the country has recorded a steady rise in infant deaths linked to HIV-related complications, marking one of the most devastating outcomes of the unchecked spread. In 2025 alone, Fijian health authorities recorded 2,016 new HIV diagnoses, according to Health Minister Antonio Lalabalavu, who emphasized that a standard outbreak-level response is no longer adequate to contain the crisis.

Health experts and non-governmental organizations have traced the rapid spread of the virus to a dangerous combination of rising intravenous drug use, unprotected sexual activity, needle sharing, and a high-risk practice known locally as “bluetoothing” or “hotspotting.” This practice, which has been tied to HIV surges across parts of Africa and the Pacific, sees multiple drug users inject the blood of an already intoxicated person to achieve a collective high. It has gained traction in Fiji for two key reasons: it allows users to split the cost of a single dose of drugs, making intoxication cheaper, and it requires only one syringe, a resource that is already difficult to access for many drug users in the country.

To address the root drivers of transmission, the Fijian government is launching a targeted syringe and needle distribution program as a core component of its emergency response. Lalabalavu confirmed that the country already holds adequate stockpiles of sterile syringes and needles, and legislative amendments will soon be introduced to parliament to clear the way for the program’s full nationwide rollout. The minister has also issued a public call for at-risk community members to access voluntary testing, stressing that stigma around HIV status remains a major barrier to care.

“No one should be ashamed, threatened, or excluded because of their HIV status,” Lalabalavu said. “Stigma drives people away from the very services that can help them.”

Alarmingly, UNAIDS data from 2025 shows that among the estimated 9,100 Fijians living with HIV, only 39% are aware of their status, and just 22% are accessing life-saving antiretroviral treatment. This falls drastically short of the global average, where 78% of people living with HIV have access to consistent treatment.

Jason Mitchell, head of Fiji’s national HIV response taskforce, warned that bringing the epidemic under control will be a years-long process, far different from the rapid two-year turnaround seen during the COVID-19 pandemic. “It will take upwards of five years for [Fiji] to get on top of the epidemic,” Mitchell told ABC News in an interview. “It’s a long-term programme, it’s not something like Covid that’s turned around in two years. HIV is very different.”

Mitchell added that the surge has placed unprecedented pressure on Fiji’s under-resourced health system. “For a health system that’s already struggling, to have people who should really be well because there’s treatment available taking up beds in hospitals and sitting in outpatient… Our clinical services has really been under a lot of pressure,” he said.

The United Nations programme on HIV and AIDS (UNAIDS) has expressed support for Fiji’s emergency declaration, noting that the move signals the urgent whole-of-society response needed to reverse the epidemic’s trajectory. Winnie Byanyima, executive director of UNAIDS, said the crisis in Fiji serves as a critical wake-up call for the global community.

“It is also a stark reminder to the world that Aids is not over,” Byanyima said. “HIV epidemics can change quickly, and countries need health and community systems that are ready to respond urgently.”

In a overcrowded pediatric ward in Dhaka, the capital of Bangladesh, 8-month-old Rojatun Jannat Ramisa fights for every breath, her small body wracked by the effects of measles. Beside her bed, her helpless parents watch, their hopes pinned on scarce medical care after traveling hundreds of kilometers for specialized treatment. Ramisa is far from alone: she is one of tens of thousands of children falling ill during a catastrophic measles outbreak that has claimed hundreds of young lives, after years of disruptions to the nation’s routine childhood immunization efforts left a large gap in population protection.

Ramisa’s mother, Ranu Akhter, recalled the alarming scale of the crisis she witnessed at her local district hospital before being referred to Dhaka Shishu Hospital, the country’s leading specialized children’s facility. “Fourteen days ago, when we were at the district hospital, every other child being treated alongside my daughter had the same telltale signs: red rashes covering their bodies, painful sores in their mouths, and raging fevers,” Akhter told the Associated Press. “It was then I understood just how far this outbreak has spread.”

As of this week, the crisis has grown steadily worse: official data from Bangladesh’s Directorate General of Health Services puts the death toll from suspected measles cases at 999 since January 1, 2025. Since the outbreak began accelerating in March, the Ministry of Health has recorded more than 166,000 suspected infections across the country, with just under 20,000 cases confirmed by laboratory testing. The outbreak first triggered alarm in March, when more than 100 children died in less than four weeks, prompting authorities to launch an emergency response.

In partnership with the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), and the Gavi vaccine alliance, the Bangladeshi government rolled out a mass emergency vaccination campaign starting in March. The effort initially targeted children between 6 months and 5 years of age, the group most vulnerable to severe measles complications, before expanding in phased stages to cover all at-risk communities nationwide.

Public health experts emphasize that measles is an extremely contagious airborne pathogen that causes high fever, respiratory distress, and a distinctive full-body rash. While many cases are mild, the disease can trigger life-threatening complications including pneumonia, brain swelling, and organ damage, particularly in infants and young children. Two doses of the measles vaccine provide robust, long-lasting protection, but public health protocols require 95% of a population to be fully immunized to achieve herd immunity — a threshold that stops transmission and protects people who cannot be vaccinated, including infants too young for the shot and immunocompromised individuals.

Just a few years ago, Bangladesh had effectively controlled measles through a decades-old routine immunization program that successfully protected generations of children from a range of preventable diseases including tuberculosis, diphtheria, whooping cough, polio, and measles. After reporting 2,410 cases in 2020, the nation saw annual cases drop to just 100 to 300 between 2021 and 2024, a public health success story that has now been upended by successive disruptions to immunization services.

Two major events created the gap in vaccination coverage that allowed the current outbreak to take hold. First, widespread lockdowns and disruptions to healthcare access during the COVID-19 pandemic left many children without their routine scheduled shots. Then, political upheaval in 2024 derailed the nation’s quadrennial mass measles vaccination campaign, a routine effort that had previously kept coverage high.

Atiqul Islam, a leading neonatal and child specialist at Dhaka Shishu Hospital and Institute, explained that the missed doses have created a large susceptible population of young children. “During 2021 and 2022, at the height of pandemic disruptions, many families were unable or afraid to bring their children in for routine vaccinations,” Islam said. “So now, children who are four or five years old have largely missed their required doses. That created a critical immunity gap. Even after the pandemic, during the previous interim government, many local vaccination centers reported consistent vaccine shortages that left the gap unaddressed.”

The crisis has also become a flashpoint for political blame-games between rival factions. Bangladesh’s current elected government, led by Prime Minister Tarique Rahman, argues that systemic planning failures under ousted former Prime Minister Sheikh Hasina and interim leader Muhammad Yunus left the country with depleted vaccine stockpiles and far below target immunization coverage. The 2024 mass vaccination campaign was directly disrupted by the mass political uprising that led to Hasina’s ouster from power in August 2024. Hasina fled into exile in India, and Yunus took over as head of an interim administration that oversaw a February 2025 election that transferred power to the current elected government. From her exile in India, Hasina has pushed back, blaming the Yunus-led interim government for the public health disaster.

At Dhaka Shishu Hospital, where frontline clinicians have been working nonstop for six months to treat infected children, Islam says the emergency response has led to modest improvements, but progress remains far too slow to stem the death toll. Many children arrive at the hospital already suffering from severe complications including pneumonia, severe diarrhea, and encephalitis — swelling of the brain that can cause permanent damage or death. “For the past six months, we have been treating measles patients continuously, without a break,” Islam said. “Our entire team is exhausted.”

At just 25 years old, New Zealand native Michael Walters had already exhausted multiple unsuccessful lymphoma treatment options in his home country. When an Australian hospital in Melbourne quoted him nearly $600,000 USD for the cutting-edge CAR-T cancer therapy, the cost was out of reach. Turning to a medical facility in Shanghai, Walters paid less than half that quoted price, and on August 18, he received the life-changing news: his cancer had entered complete remission.

Chimeric antigen receptor T-cell therapy, better known as CAR-T, is a personalized immunotherapy that works by re-engineering a patient’s own immune T-cells to identify and attack malignant cancer cells. On the surface, Walters’ success story highlights a stark global pricing gap: CAR-T therapies in China typically cost between $150,000 and $230,000, compared to $550,000 to $850,000 for comparable treatments in the United States. But low prices are far from the full picture of the growing trend of cross-border medical travel for CAR-T treatment.

As the director of the CAR-T program at MD Anderson, who has advised some international patients to pursue treatment in China, notes: China has not simply undercut global prices for CAR-T—it has scaled and industrialized the production of this personalized therapy far faster than many peer nations. Currently, nine CAR-T products have received full regulatory approval from Chinese authorities, more than any other country worldwide. Local supply chains are also tightly integrated: production laboratories are located within close proximity to major Shanghai hospitals, allowing engineered T-cells to be prepared and returned to patients for treatment in just days. For patients battling aggressive, fast-growing cancers, this reduced waiting time can make a life-or-death difference in treatment outcomes. Just this past June, Chinese regulators approved satri-cel, the world’s first CAR-T therapy indicated for a solid tumor, for use in treating certain advanced forms of stomach cancer.

That said, the rapid growth of cross-border CAR-T travel to China raises important caveats that patients and clinicians must not overlook. Two key distinctions shape the safety and efficacy of this care: regulatory clarity and realistic statistical expectations.

First, from a regulatory perspective, all hospitals offering cross-border treatment must clearly distinguish between three categories of care: treatment for an approved indication, off-label use of approved therapies, and participation in an experimental clinical trial. Patients must receive a transparent explanation of the available clinical evidence for their treatment, an independent assessment from a neutral specialist, and a detailed, credible aftercare plan before committing to travel for care.

Second, from a statistical perspective, an early complete remission for individual patients like Walters is not definitive proof that one country’s cancer care system is universally superior. Patients who can afford to travel abroad and meet eligibility criteria for CAR-T are a self-selected, non-representative group. When small boutique hospitals report that most of their few dozen international patients are cancer-free post-treatment, this is not equivalent to data from a controlled clinical trial. It cannot confirm how long remission will last, or how Chinese CAR-T outcomes compare to alternative treatments available in other nations.

Even for patients who achieve immediate remission, the treatment journey does not end after they leave the hospital. CAR-T is a living cell therapy, not a one-and-done medical procedure—it requires ongoing, coordinated care throughout a patient’s life. The therapy carries well-documented risks of severe inflammatory responses, neurological complications, and secondary infections. For many CAR-T products used to treat blood cancers, the U.S. Food and Drug Administration even mandates lifelong monitoring for secondary new cancers.

For patients who return to their home countries after treatment in China, this ongoing care often breaks down. Many returning patients lack transferable, digitized treatment records that local clinicians can easily interpret, a reliable point of contact at the Shanghai treating hospital, or a pre-arranged plan for covering costs if complications arise. Without integrated cross-border systems for sharing treatment records and follow-up data, the treating institution never gains access to long-term outcome data, and patients are left without the support they need.

The U.S. Centers for Disease Control and Prevention already recommends that patients arrange all follow-up care and financing before traveling abroad for medical treatment. Even with that guidance, local clinicians are often hesitant to take over care when treatment records, clinical responsibilities, and liability arrangements are unclear. It is critical to note that these gaps represent risks of fragmented cross-border care, not evidence that Chinese CAR-T treatment is inherently unsafe.

The core challenge now is shifting the burden of logistics away from vulnerable sick patients and their families, and making proper pre-treatment preparation a binding obligation for the institutions offering cross-border care. A small, targeted network of cross-border hospital partnerships could pilot three practical reforms to address current gaps:

First, before the CAR-T infusion is administered, the treating hospital, the patient, and a designated lead clinician at the patient’s home institution should sign a formal shared-care agreement. This agreement should explicitly outline which provider is responsible for reviewing routine test results, responding to urgent adverse events at key post-treatment milestones (30 days, 180 days, and five years, for example), and coordinating with the therapy manufacturer. This agreement should be paired with a standardized “treatment passport” that includes full details of the product used, its batch number, all pre-infusion medications, any acute complications experienced during treatment, and the full recommended monitoring schedule. This document should be shared with the patient’s home care team in a language accessible to emergency department clinicians before the patient returns home. When home countries lack specialized expertise in CAR-T management, the treating institution should help arrange specialized support rather than leaving the problem to patients and their families. Clarifying responsibilities ahead of treatment eliminates confusion when complications arise after care.

Second, all pricing for cross-border treatment should be fully transparent. Upfront quotations should break down all costs, including the therapy itself, inpatient hospitalization, potential intensive care needs, patient and family accommodation, and planned follow-up. Explicit terms for covering the cost of complication management should be included: this is not to guarantee a fixed, low price, but to make any exclusions clear before a patient commits to treatment. Where legally permitted, public and private insurance payers could pilot coverage agreements with vetted overseas CAR-T centers, requiring verifiable clinical evidence for the proposed treatment, confirmation of adequate facility standards, and pre-arranged funding for aftercare. Cross-border price comparisons should evaluate total treatment cost and long-term outcomes, not just rely on advertised base prices. Patients should never be pressured to travel abroad to cut payer costs, but they also should not be abandoned by their home care system if they choose to pursue this option.

Third, global cell therapy registries should be opened to cross-border data sharing. Existing national registries for cell therapies provide a ready foundation for this work. With explicit patient consent and compliance with global data protection laws, participating hospitals should link data from treatments administered abroad to follow-up care in the patient’s home country, and report standardized outcomes including overall survival, cancer relapse, serious adverse events, and cases of lost follow-up—not just positive early remission results. This system would allow a hematologist in Maryland, for example, to access full verified data about a specific therapy batch administered in Shanghai, and outcomes from dozens of international patients would contribute to rigorous clinical evidence rather than just anecdotal success stories.

None of these reforms require global harmonization of drug approvals, nor do they demand that any nation declare China’s CAR-T system superior or untrustworthy. They simply require acknowledging the new reality: patients are already moving across borders to access cutting-edge care far faster than global medical institutions have adapted to support them. A therapy is only as good as the long-term care and follow-up that accompanies it.

China has the opportunity to set a global standard for responsible cross-border CAR-T care, and any other nation seeking to attract international medical travelers should be required to meet that same standard. The most meaningful metric to track progress is not how many foreign patients arrive in Shanghai on medical visas, but how many of those patients can be traced and have their long-term outcomes counted five years after treatment.